BeiGene selects GE Healthcare to help manufacture cancer antibody

GE Healthcare has teamed up with biotechnology company BeiGene to help manufacture its cancer monoclonal antibodies (mAbs).

BeiGene has selected GE Healthcare’s off-the-shelf biomanufacturing facility KuBio to produce its cancer monoclonal antibodies. KuBio facilities are prefabricated constructions based on single-use technologies which are designed to reduce time to market for companies around the world.

BeiGene’s KuBio will be based in Guangzhou, China, where an increasing number of biotech firms are establishing operations. KuBio facilities can also yield productivity by increasing the number of lots manufactured, reducing maintenance requirements and shortening downtime between batches and products. They can be constructed in 18 months which is 50% faster than traditional manufacturing facilities, which usually require three years before they are fully commissioned and qualified.

The first phase of BeiGene’s KuBio is expected to be completed and operational in 2019. BeiGene is already using GE Healthcare’s FlexFactory, an integrated biomanufacturing platform in its existing manufacturing plant in Suzhou, China to manufacture mAbs for clinical trials.

Jonathan Liu, senior vice president, Biomanufacturing and Head of Biologics of BeiGene, said: “To realise our mission of developing innovative solutions to help cancer patients in China and globally, BeiGene is constantly focused on quality and agility, not only in R&D, but also in manufacturing. We believe that the implementation of the KUBio facility will help us to produce antibody-based medicines with a high standard of quality to address the unmet and urgent needs of cancer patients.”

“BeiGene is one of the leading biotechnology companies from China, striving to serve patients with new cancer therapies worldwide. We believe that KUBio will help BeiGene to reach the China and global markets more quickly, using a flexible and reliable manufacturing platform that meets the highest regulatory standards,” said Olivier Loeillot, general manager, BioProcess, GE Healthcare Life Sciences.

Let's block ads! (Why?)